NVRO:NYE-Nevro Corp (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 92.06

Change

0.00 (0.00)%

Market Cap

USD 3.21B

Volume

0.45M

Avg Analyst Target

USD 121.84 (+32.35%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Nevro Corp (NVRO) Stock Analysis:
Based on the Nevro Corp stock forecasts from 10 analysts, the average analyst target price for Nevro Corp is USD 121.84 over the next 12 months. Nevro Corp’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Nevro Corp is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Nevro Corp’s stock price was USD 92.06. Nevro Corp’s stock price has changed by +6.33% over the past week, +6.25% over the past month and -47.45% over the last year.

About

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatme ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-17 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABT Abbott Laboratories

N/A

USD226.62B 31.80 19.97
MDT Medtronic plc

N/A

USD145.95B 31.30 19.83
SYK Stryker Corporation

N/A

USD100.61B 53.69 29.98
EW Edwards Lifesciences Corporati..

N/A

USD73.83B 50.86 56.15
BSX Boston Scientific Corporation

N/A

USD63.93B 58.34 24.46
PHG Koninklijke Philips N.V

N/A

USD30.29B 7.28 30.12
ZBH Zimmer Biomet Holdings Inc

N/A

USD26.61B 32.54 16.05
STE STERIS plc

N/A

USD23.46B 85.28 36.60
BIO-B Bio-Rad Laboratories Inc

N/A

USD18.78B 2.83 2.44
BIO Bio-Rad Laboratories Inc

N/A

USD18.78B 2.85 2.44

ETFs Containing NVRO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.56% 90% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.56% 90% A- 95% A
Trailing 12 Months  
Capital Gain -47.45% 16% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.45% 16% F 5% F
Trailing 5 Years  
Capital Gain 3.30% 11% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.30% 11% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 27.19% 60% D- 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.19% 56% F 85% B
Risk Return Profile  
Volatility (Standard Deviation) 66.33% 20% F 12% F
Risk Adjusted Return 40.98% 32% F 45% F
Market Capitalization 3.21B 46% F 66% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.47 18% F 10% F
Price / Cash Flow Ratio 2,697.96 4% F 0% N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -31.00% 25% F 12% F
Return on Invested Capital -11.85% 28% F 9% F
Return on Assets -6.03% 25% F 7% F
Debt to Equity Ratio 36.50% 63% D 70% C-
Technical Ratios  
Short Ratio 4.66 21% F 16% F
Short Percent 9.11% 19% F 30% F
Beta 1.03 48% F 52% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector